COVID-19 Vaccine

RSV Vaccine Flu-COVID-19 Combination Vaccine

Sanofi and Novavax Forge Major Alliance, Boosting Novavax's Market Position

The $1.2 billion deal includes co-commercialization of COVID-19 vaccines and development of new flu-COVID combo vaccines, marking a significant turnaround for Novavax.

5 ARTICLES

last yr.

Moderna Reports Sharp Decline in COVID-19 Vaccine Sales, Outperforms Expectations

8 ARTICLES

last yr.

Moderna Posts Large Q3 Loss With Weaker Vaccine Demand, Projects $4B in Sales for 2024, Investors Concerned